US3480613A
(en)
|
1967-07-03 |
1969-11-25 |
Merck & Co Inc |
2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
ES8702440A1
(es)
|
1984-10-04 |
1986-12-16 |
Monsanto Co |
Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
DK0527815T3
(da)
|
1990-04-06 |
2000-11-06 |
Genelabs Tech Inc |
Hepatitis C-virus-epitop
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
DE4207363A1
(de)
|
1992-03-04 |
1993-09-09 |
Max Delbrueck Centrum |
Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
|
US5610054A
(en)
|
1992-05-14 |
1997-03-11 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecule targeted against Hepatitis C virus
|
US6423489B1
(en)
|
1992-09-10 |
2002-07-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
WO1994005813A1
(en)
|
1992-09-10 |
1994-03-17 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Compositions and methods for treatment of hepatitis c virus-associated diseases
|
US6391542B1
(en)
|
1992-09-10 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6995146B2
(en)
|
1992-09-10 |
2006-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6433159B1
(en)
|
1992-09-10 |
2002-08-13 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus associated diseases
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
WO1994019012A2
(en)
|
1993-02-24 |
1994-09-01 |
Wang Jui H |
Compositions and methods of application of reactive antiviral polymers
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
WO1995003056A1
(fr)
|
1993-07-19 |
1995-02-02 |
Tokyo Tanabe Company Limited |
Inhibiteur de proliferation du virus de l'hepatite c
|
DE4415539C2
(de)
|
1994-05-03 |
1996-08-01 |
Osama Dr Dr Med Omer |
Pflanzen mit virustatischer und antiviraler Wirkung
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
DE4432623A1
(de)
|
1994-09-14 |
1996-03-21 |
Huels Chemische Werke Ag |
Verfahren zur Bleichung von wäßrigen Tensidlösungen
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
JP3786447B2
(ja)
|
1995-03-31 |
2006-06-14 |
エーザイ株式会社 |
C型肝炎の予防・治療剤
|
ATE268591T1
(de)
|
1995-06-27 |
2004-06-15 |
Takeda Chemical Industries Ltd |
Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
AU2064297A
(en)
|
1996-02-29 |
1997-09-16 |
Immusol, Inc |
Hepatitis c virus ribozymes
|
US5633388A
(en)
|
1996-03-29 |
1997-05-27 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5830905A
(en)
|
1996-03-29 |
1998-11-03 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5990276A
(en)
|
1996-05-10 |
1999-11-23 |
Schering Corporation |
Synthetic inhibitors of hepatitis C virus NS3 protease
|
US5891874A
(en)
|
1996-06-05 |
1999-04-06 |
Eli Lilly And Company |
Anti-viral compound
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
US5837257A
(en)
|
1996-07-09 |
1998-11-17 |
Sage R&D |
Use of plant extracts for treatment of HIV, HCV and HBV infections
|
GB9617177D0
(en)
|
1996-08-15 |
1996-09-25 |
Kvaerner H & G Offshore Ltd |
Downhole valve actuation
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
JP3927630B2
(ja)
|
1996-09-27 |
2007-06-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウイルス感染症の予防・治療剤
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
BR9712544B1
(pt)
|
1996-10-18 |
2013-10-22 |
|
Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
|
EP0839525B1
(en)
|
1996-10-31 |
2004-08-04 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
GB9623908D0
(en)
|
1996-11-18 |
1997-01-08 |
Hoffmann La Roche |
Amino acid derivatives
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
EP0946169B1
(en)
|
1996-12-20 |
2003-02-26 |
Takeda Chemical Industries, Ltd. |
Method of producing a sustained-release preparation
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
US6004933A
(en)
|
1997-04-25 |
1999-12-21 |
Cortech Inc. |
Cysteine protease inhibitors
|
GB9708611D0
(en)
|
1997-04-28 |
1997-06-18 |
Univ Cardiff |
Chemical compounds
|
KR100630506B1
(ko)
|
1997-06-30 |
2006-09-29 |
메르츠 파마 게엠베하 운트 코. 카가아 |
Nmda 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물, 이를 함유하는 제약학적 조성물 및 이것으로 치료하는 방법
|
EP1012180B1
(en)
|
1997-08-11 |
2004-12-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor peptide analogues
|
EP1058686B1
(en)
|
1998-02-25 |
2006-11-02 |
Emory University |
2'-fluoronucleosides
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
GB9821058D0
(en)
|
1998-09-28 |
1998-11-18 |
Univ Cardiff |
Chemical compound
|
AU772478B2
(en)
|
1999-02-12 |
2004-04-29 |
Glaxo Group Limited |
Phosphoramidate, and mono-, DI-, and tri-phosphate esters of (1R,CIS)-4-(6-amino-9H-purin-9-YL)-2-cyclopentene-1- methanol as antiviral agents
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US6566365B1
(en)
|
1999-11-04 |
2003-05-20 |
Biochem Pharma Inc. |
Method for the treatment of Flaviviridea viral infection using nucleoside analogues
|
EA200200778A1
(ru)
|
2000-02-18 |
2003-06-26 |
Шайре Байокем Инк. |
СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С В ОРГАНИЗМЕ ХОЗЯИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВ ФЛАВИВИРУСА, СОЕДИНЕНИЕ ФОРМУЛЫ Ib - АКТИВНЫЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С ИЛИ ФЛАВИВИРУСА (ВАРИАНТЫ)
|
BR0110023A
(pt)
|
2000-04-13 |
2003-12-30 |
Pharmasset Ltd |
Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite
|
GB0009486D0
(en)
|
2000-04-17 |
2000-06-07 |
Univ Cardiff |
Chemical compounds
|
GB0011203D0
(en)
|
2000-05-09 |
2000-06-28 |
Univ Cardiff |
Chemical compounds
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
EP1294735A2
(en)
|
2000-05-26 |
2003-03-26 |
Novirio Pharmaceuticals Limited |
Methods and compositions for treating flaviviruses and pestiviruses
|
EP1301527A2
(en)
|
2000-07-21 |
2003-04-16 |
Corvas International, Inc. |
Peptides as ns3-serine protease inhibitors of hepatitis c virus
|
RU2003105221A
(ru)
|
2000-07-21 |
2004-09-20 |
Шеринг Корпорейшн (US) |
Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
US20030008841A1
(en)
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
CN1133642C
(zh)
|
2000-10-09 |
2004-01-07 |
清华大学 |
核苷5’-硫代磷酰氨基酸酯化合物
|
KR101201552B1
(ko)
|
2000-10-18 |
2012-11-15 |
파마셋 인코포레이티드 |
바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
|
BR0115447A
(pt)
|
2000-11-20 |
2005-10-18 |
Bristol Myers Squibb Co |
Inibidores de tripeptìdeo de hepatite c
|
WO2002048172A2
(en)
|
2000-12-12 |
2002-06-20 |
Schering Corporation |
Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
|
US6727366B2
(en)
|
2000-12-13 |
2004-04-27 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
AU2002230763A1
(en)
|
2000-12-13 |
2008-01-03 |
Bristol-Myers Squibb Pharma Company |
Inhibitors of hepatitis c virus ns3 protease
|
AU2002232660A1
(en)
|
2000-12-15 |
2002-06-24 |
Pharmasset Ltd. |
Antiviral agents for treatment of flaviviridae infections
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
RS50236B
(sr)
|
2001-01-22 |
2009-07-15 |
Merck & Co.Inc., |
Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
|
EP1363927A2
(en)
|
2001-03-01 |
2003-11-26 |
Pharmasset Limited |
Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
|
US20040209831A1
(en)
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
WO2003070750A2
(en)
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc |
Rna interference mediated inhibition of hepatitis c virus
|
GB0112617D0
(en)
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
JP2004534830A
(ja)
|
2001-06-21 |
2004-11-18 |
グラクソ グループ リミテッド |
Hcvにおけるヌクレオシド化合物
|
US7022323B2
(en)
|
2001-06-26 |
2006-04-04 |
Progenics Pharmaceuticals, Inc. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
US20040006002A1
(en)
|
2001-09-28 |
2004-01-08 |
Jean-Pierre Sommadossi |
Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
|
EP1435974A4
(en)
|
2001-09-28 |
2006-09-06 |
Idenix Cayman Ltd |
METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
|
US6867185B2
(en)
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
CA2370396A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
CA2369970A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US7323453B2
(en)
|
2002-02-13 |
2008-01-29 |
Merck & Co., Inc. |
Methods of inhibiting orthopoxvirus replication with nucleoside compounds
|
AU2003217863B9
(en)
|
2002-02-28 |
2009-10-29 |
Biota Scientific Management Pty Ltd |
Nucleotide mimics and their prodrugs
|
AU2003301959A1
(en)
|
2002-05-20 |
2004-06-03 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl p1' hepatitis c virus inhibitors
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
ATE481106T1
(de)
|
2002-05-20 |
2010-10-15 |
Bristol Myers Squibb Co |
Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
|
ATE503764T1
(de)
|
2002-05-20 |
2011-04-15 |
Bristol Myers Squibb Co |
Inhibitoren des hepatitis-c-virus
|
AU2003241621A1
(en)
|
2002-05-24 |
2003-12-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
WO2003105770A2
(en)
|
2002-06-17 |
2003-12-24 |
Merck & Co., Inc. |
Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
AU2003269890A1
(en)
|
2002-06-21 |
2004-01-06 |
Isis Pharmaceuticals, Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US20060234962A1
(en)
|
2002-06-27 |
2006-10-19 |
Olsen David B |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
MXPA04012779A
(es)
|
2002-06-28 |
2005-08-19 |
Idenix Cayman Ltd |
Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
|
CN101172993A
(zh)
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
KR20050035194A
(ko)
|
2002-06-28 |
2005-04-15 |
이데닉스 (케이만) 리미티드 |
플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘
|
RS114004A
(en)
|
2002-06-28 |
2007-02-05 |
Idenix (Cayman) Limited, |
Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
|
JP2005533108A
(ja)
|
2002-07-16 |
2005-11-04 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体
|
AU2003256619A1
(en)
|
2002-07-24 |
2004-02-09 |
Isis Pharmaceuticals, Inc. |
Pyrrolopyrimidine thionucleoside analogs as antivirals
|
US20040067877A1
(en)
|
2002-08-01 |
2004-04-08 |
Schinazi Raymond F. |
2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
US20040229840A1
(en)
|
2002-10-29 |
2004-11-18 |
Balkrishen Bhat |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
CN1849142A
(zh)
|
2002-11-15 |
2006-10-18 |
埃迪尼克斯(开曼)有限公司 |
2′-支链核苷和黄病毒突变
|
TWI332507B
(en)
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
US7598373B2
(en)
|
2002-12-12 |
2009-10-06 |
Idenix Pharmaceuticals, Inc. |
Process for the production of 2-C-methyl-D-ribonolactone
|
US7601709B2
(en)
|
2003-02-07 |
2009-10-13 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
AR043006A1
(es)
|
2003-02-12 |
2005-07-13 |
Merck & Co Inc |
Proceso para preparar ribonucleosidos ramificados
|
NZ542342A
(en)
|
2003-04-25 |
2009-05-31 |
Gilead Sciences Inc |
Antiviral phosphonate analogs
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
WO2004096285A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-infective phosphonate conjugates
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
WO2005020884A2
(en)
|
2003-05-14 |
2005-03-10 |
Idenix (Cayman) Limited |
Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
|
WO2005020885A2
(en)
|
2003-05-21 |
2005-03-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
|
EP2345661A1
(en)
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
DE602004003389T2
(de)
|
2003-06-19 |
2007-09-13 |
F. Hoffmann-La Roche Ag |
Verfahren zur herstellung von 4'-azidonukleosidderivaten
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
US20050043266A1
(en)
|
2003-07-25 |
2005-02-24 |
Sumedha Jayasena |
Short interfering RNA as an antiviral agent for hepatitis C
|
KR20060130027A
(ko)
|
2003-10-10 |
2006-12-18 |
버텍스 파마슈티칼스 인코포레이티드 |
세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의억제제
|
GB0401088D0
(en)
|
2004-01-19 |
2004-02-18 |
Univ Cardiff |
Phosphoramidate derivatives
|
EP2980095A1
(en)
|
2004-03-04 |
2016-02-03 |
K.U.Leuven Research & Development |
Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
|
EP1758453B1
(en)
|
2004-06-15 |
2014-07-16 |
Merck Sharp & Dohme Corp. |
C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
|
EP1912643A2
(en)
|
2004-06-23 |
2008-04-23 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CA2571079A1
(en)
|
2004-06-24 |
2006-02-02 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
US7705146B2
(en)
|
2004-06-28 |
2010-04-27 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor peptide analogs
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
AU2005330489B2
(en)
|
2004-07-27 |
2011-08-25 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates as anti HIV agents
|
EP1794172B1
(en)
|
2004-08-23 |
2009-07-15 |
F.Hoffmann-La Roche Ag |
Antiviral 4'-azido-nucleosides
|
WO2006026352A1
(en)
|
2004-08-27 |
2006-03-09 |
Schering Corporation |
Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
|
WO2007001406A2
(en)
|
2004-10-05 |
2007-01-04 |
Chiron Corporation |
Aryl-containing macrocyclic compounds
|
CA2584367A1
(en)
|
2004-10-21 |
2006-06-22 |
Merck & Co., Inc. |
Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
|
US8399428B2
(en)
|
2004-12-09 |
2013-03-19 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
EP1853617A1
(en)
|
2005-02-28 |
2007-11-14 |
Genelabs Technologies, Inc. |
Tricyclic-nucleoside prodrugs for treating viral infections
|
WO2006094347A1
(en)
|
2005-03-08 |
2006-09-14 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
CA2600359A1
(en)
|
2005-03-09 |
2006-09-09 |
Idenix (Cayman) Limited |
Nucleosides with non-natural bases as anti-viral agents
|
WO2006116557A1
(en)
*
|
2005-04-25 |
2006-11-02 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
AU2006242475B2
(en)
|
2005-05-02 |
2011-07-07 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
WO2007027248A2
(en)
|
2005-05-16 |
2007-03-08 |
Valeant Research & Development |
3', 5' - cyclic nucleoside analogues for treatment of hcv
|
EP1915054A4
(en)
|
2005-08-09 |
2010-09-01 |
Merck Sharp & Dohme |
CYCLIC ACETAL DERIVATIVES OF RIBONUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
|
WO2007022073A2
(en)
|
2005-08-12 |
2007-02-22 |
Merck & Co., Inc. |
Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
|
CN101287472B
(zh)
*
|
2005-08-15 |
2011-10-12 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
|
EA200800932A1
(ru)
|
2005-09-26 |
2008-10-30 |
Фармассет, Инк. |
Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
|
CN101511375B
(zh)
|
2005-12-02 |
2012-09-05 |
耶鲁大学 |
L-胞嘧啶核苷类似物在制备用于治疗癌症和其它病症或疾病状态的药物中的应用
|
RU2422454C2
(ru)
|
2005-12-09 |
2011-06-27 |
Ф. Хоффманн-Ля Рош Аг |
Антивирусные нуклеозиды
|
EP1976382B1
(en)
|
2005-12-23 |
2013-04-24 |
IDENIX Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
CA2637879A1
(en)
|
2006-02-14 |
2007-08-23 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
CN101460488A
(zh)
|
2006-04-04 |
2009-06-17 |
弗·哈夫曼-拉罗切有限公司 |
用于hcv治疗的3’,5’-二-o-酰化核苷
|
US7842672B2
(en)
|
2006-07-07 |
2010-11-30 |
Gilead Sciences, Inc. |
Phosphonate inhibitors of HCV
|
MX2009003398A
(es)
|
2006-09-27 |
2009-08-12 |
Coley Pharm Gmbh |
Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
|
CN101573370B
(zh)
|
2006-10-10 |
2013-09-11 |
美迪维尔公司 |
Hcv核苷类抑制剂
|
WO2008045419A1
(en)
|
2006-10-10 |
2008-04-17 |
Pharmasset, Inc. |
Preparation of nucleosides ribofuranosyl pyrimidines
|
GB0623493D0
(en)
|
2006-11-24 |
2007-01-03 |
Univ Cardiff |
Chemical compounds
|
DE602007008616D1
(de)
|
2006-12-11 |
2010-09-30 |
Hoffmann La Roche |
Verfahren zur herstellung von 4'-azidocytidinderivaten
|
WO2008079206A1
(en)
|
2006-12-20 |
2008-07-03 |
Merck & Co., Inc. |
Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2008083465A1
(en)
|
2007-01-08 |
2008-07-17 |
University Health Network |
Pyrimidine derivatives as anticancer agents
|
US8324179B2
(en)
|
2007-02-09 |
2012-12-04 |
Gilead Sciences, Inc. |
Nucleoside analogs for antiviral treatment
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
MX2009012433A
(es)
|
2007-05-14 |
2010-04-30 |
Rfs Pharma Llc |
Azido nucleosidos de purina para el tratamiento de infecciones virales.
|
US20090048189A1
(en)
|
2007-08-15 |
2009-02-19 |
Genelabs Technologies, Inc. |
Tricyclic-nucleoside compounds for treating viral infections
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
US20090318380A1
(en)
|
2007-11-20 |
2009-12-24 |
Pharmasset, Inc. |
2',4'-substituted nucleosides as antiviral agents
|
US20090176732A1
(en)
|
2007-12-21 |
2009-07-09 |
Alios Biopharma Inc. |
Protected nucleotide analogs
|
CN107753499A
(zh)
|
2008-04-03 |
2018-03-06 |
春堤制药公司 |
用于治疗病毒感染的化合物和方法
|
BRPI0911410A2
(pt)
|
2008-04-23 |
2015-10-06 |
Gilead Sciences Inc |
análogos de carba-nucleosídeo para tratamento antiviral
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
AU2009277172B2
(en)
|
2008-07-02 |
2014-05-29 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
GB0815968D0
(en)
|
2008-09-03 |
2008-10-08 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
AU2009298802A1
(en)
|
2008-09-23 |
2010-04-08 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
SG172361A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside analogs
|
AR074897A1
(es)
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
AU2009329872B2
(en)
|
2008-12-23 |
2016-07-07 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
CA2749394A1
(en)
|
2009-01-09 |
2010-07-15 |
University College Of Cardiff Consultants Limited |
Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
KR101774429B1
(ko)
|
2009-02-06 |
2017-09-04 |
코크리스탈 파마, 아이엔씨. |
암 및 바이러스 감염 치료용 퓨린 뉴클레오시드 모노포스페이트 프로드럭
|
PE20160858A1
(es)
|
2009-02-10 |
2016-09-03 |
Gilead Sciences Inc |
Analogos carba-nucleosidicos para tratamiento antiviral
|
WO2010108135A1
(en)
|
2009-03-20 |
2010-09-23 |
Alios Biopharma, Inc. |
Protected nucleotide analogs
|
EP2408306A4
(en)
|
2009-03-20 |
2012-11-07 |
Alios Biopharma Inc |
SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TW201107342A
(en)
*
|
2009-05-20 |
2011-03-01 |
Chimerix Inc |
Compounds, compositions and methods for treating viral infection
|
US8728725B2
(en)
|
2009-07-06 |
2014-05-20 |
Trilink Biotechnologies |
Chemically modified ligase cofactors, donors and acceptors
|
US8455451B2
(en)
|
2009-09-21 |
2013-06-04 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
US7973013B2
(en)
|
2009-09-21 |
2011-07-05 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
US20100077085A1
(en)
|
2009-09-23 |
2010-03-25 |
Joseph Chyam Cohen |
Systems and method for configuring display resolution in a terminal server environment
|
CN102686599B
(zh)
|
2009-09-29 |
2016-10-05 |
杨森产品有限公司 |
核苷的氨基磷酸酯衍生物
|
US8816074B2
(en)
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
JP5779799B2
(ja)
|
2009-11-16 |
2015-09-16 |
ユニバーシティ オブ ジョージア リサーチ ファウンデーション, インコーポレーテッド |
2’−フルオロ−6’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法
|
DK2528930T3
(da)
|
2010-01-28 |
2013-11-11 |
Hoffmann La Roche |
4'-azido-nukleosider som anti-hcv-forbindelser
|
CA2791630A1
(en)
|
2010-03-04 |
2011-09-09 |
Enanta Pharmaceuticals, Inc. |
Combination pharmaceutical agents as inhibitors of hcv replication
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
EP2752422B1
(en)
|
2010-03-31 |
2017-08-16 |
Gilead Pharmasset LLC |
Stereoselective synthesis of phosphorus containing actives
|
MX2012011222A
(es)
|
2010-04-01 |
2013-01-18 |
Centre Nat Rech Scient |
Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
|
TW201201815A
(en)
*
|
2010-05-28 |
2012-01-16 |
Gilead Sciences Inc |
1'-substituted-carba-nucleoside prodrugs for antiviral treatment
|
WO2011156757A1
(en)
|
2010-06-10 |
2011-12-15 |
Gilead Sciences, Inc. |
Combination of anti-hcv compounds with ribavirin for the treatment of hcv
|
KR20200052384A
(ko)
|
2010-07-19 |
2020-05-14 |
길리애드 사이언시즈, 인코포레이티드 |
부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
|
TW201305185A
(zh)
|
2010-09-13 |
2013-02-01 |
Gilead Sciences Inc |
用於抗病毒治療之2’-氟取代之碳-核苷類似物
|
NZ607996A
(en)
|
2010-09-22 |
2014-07-25 |
Alios Biopharma Inc |
Substituted nucleotide analogs
|
WO2012040126A1
(en)
*
|
2010-09-22 |
2012-03-29 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
WO2012040124A1
(en)
|
2010-09-22 |
2012-03-29 |
Alios Biopharma, Inc. |
Azido nucleosides and nucleotide analogs
|
WO2012048013A2
(en)
*
|
2010-10-06 |
2012-04-12 |
Inhibitex, Inc. |
Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
|
WO2012062870A1
(en)
|
2010-11-10 |
2012-05-18 |
Janssen Products, Lp |
Uracyl spirooxetane nucleoside phosphoramidates
|
ES2605433T3
(es)
|
2010-11-10 |
2017-03-14 |
Janssen Products, L.P. |
Fosforamidatos de espironucleósido oxetánico uracílico
|
ES2716158T3
(es)
|
2010-11-30 |
2019-06-10 |
Gilead Pharmasset Llc |
2'-spiro-nucleótidos para el tratamiento de hepatitis C
|
CA2822037A1
(en)
|
2010-12-20 |
2012-06-28 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
EP2655392B1
(en)
|
2010-12-22 |
2018-04-18 |
Alios Biopharma, Inc. |
Cyclic nucleotide analogs
|
EP2658857B1
(en)
|
2010-12-29 |
2016-11-02 |
Inhibitex, Inc. |
Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
|
US9156874B2
(en)
|
2011-01-03 |
2015-10-13 |
Nanjing Molecular Research, Inc. |
Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
|
US9095599B2
(en)
|
2011-01-03 |
2015-08-04 |
Nanjing Molecular Research, Inc. |
O-(substituted benzyl) phosphoramidate compounds and therapeutic use
|
US9085599B2
(en)
|
2011-03-16 |
2015-07-21 |
Enanta Pharmaceuticals, Inc. |
2′allene-substituted nucleoside derivatives
|
WO2012154321A1
(en)
*
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
JP2014515023A
(ja)
|
2011-04-13 |
2014-06-26 |
メルク・シャープ・アンド・ドーム・コーポレーション |
2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
|
EA201391264A1
(ru)
|
2011-04-13 |
2014-03-31 |
Джилид Сайэнс, Инк. |
1'-замещенные пиримидиновые n-нуклеозидные аналоги для противовирусного лечения
|
AU2012242978A1
(en)
|
2011-04-13 |
2013-10-24 |
Merck Sharp & Dohme Corp. |
2'-Cyano Substituted Nucleoside Derivatives and methods of use thereof for the treatment of viral diseases
|
EP2697242B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
RU2013125713A
(ru)
|
2011-05-19 |
2015-06-27 |
Рфс Фарма, Ллк |
Пуринмонофосфатные пролекарства для лечения вирусных инфекций
|
US9416154B2
(en)
|
2011-07-13 |
2016-08-16 |
Merck Sharp & Dohme Corp. |
5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US9408863B2
(en)
|
2011-07-13 |
2016-08-09 |
Merck Sharp & Dohme Corp. |
5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
|
US20140315850A1
(en)
|
2011-07-19 |
2014-10-23 |
Nanjing Molecular Research, Inc. |
2',3'-Dideoxy-2'-alpha-Fluoro-2'-beta-C-Methylnucleosides and Prodrugs Thereof
|
JP2014526474A
(ja)
|
2011-09-12 |
2014-10-06 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
TW201329096A
(zh)
|
2011-09-12 |
2013-07-16 |
Idenix Pharmaceuticals Inc |
經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
|
US8575119B2
(en)
|
2011-09-23 |
2013-11-05 |
Enanta Pharmaceuticals, Inc. |
2′-chloroacetylenyl substituted nucleoside derivatives
|
EP2768838A1
(en)
|
2011-10-14 |
2014-08-27 |
IDENIX Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013084165A1
(en)
|
2011-12-05 |
2013-06-13 |
Medivir Ab |
Hcv polymerase inhibitors
|
CA2856179C
(en)
|
2011-12-20 |
2017-02-28 |
F. Hoffmann-La Roche Ag |
2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
|
SI2794628T1
(sl)
|
2011-12-20 |
2017-07-31 |
Riboscience Llc |
4'-azido-3'-fluoro substituirani nukleozidni derivati kot inhibitorji podvojevanja RNA HCV
|
WO2013106344A1
(en)
|
2012-01-12 |
2013-07-18 |
Ligand Pharmaceuticals, Inc. |
2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
|
NZ702744A
(en)
|
2012-05-22 |
2016-12-23 |
Idenix Pharmaceuticals Llc |
D-amino acid compounds for liver disease
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
US9192621B2
(en)
|
2012-09-27 |
2015-11-24 |
Idenix Pharmaceuticals Llc |
Esters and malonates of SATE prodrugs
|
EA030189B8
(ru)
|
2012-10-08 |
2018-10-31 |
Иденикс Фармасьютикалз Ллс |
Аналоги 2'-хлоронуклеозидов для инфекции вгс
|
WO2014059902A1
(en)
|
2012-10-17 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
|
US9242988B2
(en)
|
2012-10-17 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
AR092959A1
(es)
|
2012-10-17 |
2015-05-06 |
Merck Sharp & Dohme |
Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
|
US20140112886A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
EP2938624A1
(en)
|
2012-11-14 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
WO2014078427A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
WO2014124430A1
(en)
|
2013-02-11 |
2014-08-14 |
Emory University |
Nucleotide and nucleoside therapeutic compositions and uses related thereto
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
EP2970357A1
(en)
|
2013-03-13 |
2016-01-20 |
IDENIX Pharmaceuticals, Inc. |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
RU2534613C2
(ru)
|
2013-03-22 |
2014-11-27 |
Александр Васильевич Иващенко |
Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
|
CN103848876B
(zh)
|
2013-03-25 |
2016-05-11 |
安徽贝克联合制药有限公司 |
一种核苷磷酰胺前药及其制备方法和其应用
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
US9765107B2
(en)
|
2013-06-18 |
2017-09-19 |
Merck Sharp & Dohme Corp. |
Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
US20160280729A1
(en)
|
2013-11-20 |
2016-09-29 |
Idenix Pharmaceuticals Llc |
Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
|
KR20160099090A
(ko)
|
2013-11-27 |
2016-08-19 |
아이데닉스 파마슈티칼스 엘엘씨 |
간암의 치료를 위한 뉴클레오티드
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
CN103848877B
(zh)
|
2013-12-16 |
2016-08-24 |
安徽贝克联合制药有限公司 |
核苷环磷酸酯化合物及其制备方法和其应用
|
WO2015095305A1
(en)
|
2013-12-17 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
EP3113763A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|